Sign in →

Test Code ADMAB ADAMTS 13 Antibody, Plasma


Ordering Guidance


Consider ordering in patients to aid in distinguishing between congenital thrombotic thrombocytopenic purpura (TTP) and acquired autoimmune TTP.



Specimen Required


Patient Preparation:

Fasting: 8 hours, preferred

Collection Container/Tube: Light-blue top (3.2% sodium citrate)

Submission Container/Tube: Polypropylene plastic vial

Specimen Volume: 1 mL plasma

Collection Instructions:

1. Specimen must be collected prior to replacement therapy.

2. For complete instructions, see Coagulation Guidelines for Specimen Handling and Processing.

3. Centrifuge, transfer all plasma into a plastic vial, and centrifuge plasma again.

4. Aliquot plasma into a separate plastic vial, leaving 0.25 mL in the bottom of centrifuged vial.

5. Freeze plasma immediately (no longer than 4 hours after collection) at -20° C or, ideally, below -40° C.

Specimen Stability Information: Frozen 21 months

Additional Information:

1. Double-centrifuged specimen is critical for accurate results.

2. Each coagulation assay requested should have its own vial.


Forms

If not ordering electronically, complete, print, and send a Coagulation Test Request (T753) with the specimen.

Useful For

Assisting with the diagnosis and monitoring of congenital, immune, or acquired thrombotic thrombocytopenic purpura

Method Name

Enzyme-Linked Immunosorbent Assay (ELISA)

Reporting Name

ADAMTS 13 Antibody, P

Specimen Type

Plasma Na Cit

Specimen Minimum Volume

1 mL

Specimen Stability Information

Specimen Type Temperature Time
Plasma Na Cit Frozen

Reference Values

Negative: <12 U/mL

Borderline positive: 12-15 U/mL

Positive: >15 U/mL

Interpretation

Greater than or equal to 12 U/mL ADAMTS13 antibody is indicative of immune mediated thrombotic thrombocytopenic purpura in an appropriate clinical setting.

Clinical Reference

1. Dainese C, Valeri F, Bruno B, Borchiellini A. Anti-ADAMTS13 autoantibodies: From pathophysiology to prognostic impact-A review for clinicians. J Clin Med. 2023;12(17):5630. doi:10.3390/jcm12175630.

2. Nakashima MO, Zhang X, Rogers HJ, et al. Validation of a panel of ADAMTS13 assays for diagnosis of thrombotic thrombocytopenic purpura: activity, functional inhibitor, and autoantibody test. Int J Lab Hematol. 2016;38(5):550-559. doi:10.1111/ijlh.12542

3. Alwan F, Vendramin C, Vanhoorelbeke K, et al. Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura. Blood. 2017;130(4):446-471. doi:10.1182/blood-2016-12-758656

4. Yang S, Jin M, Lin S, Cataland S, Wu H. ADAMTS13 activity and antigen during therapy and follow-up of patients with idiopathic thrombotic thrombocytopenic purpura: correlation with clinical outcome. Haematologica. 2011;96(10):1521-1527. doi:10.3324/haematol.2011.042945

5. Masias C, Cataland SR. The role of ADAMTS13 testing in the diagnosis and management of thrombotic microangiopathies and thrombosis. Blood. 2018;132(9):903-910. doi:10.1182/blood-2018-02-791533

6. Starke R, Machin S, Scully M, Purdy G, Mackie I. The clinical utility of ADAMTS13 activity, antigen and autoantibody assays in thrombotic thrombocytopenic purpura. Br J Haematol. 2007;136(4):649-655. doi:10.1111/j.1365-2141.2006.06471.x

7. MacArthur TA, Goswami J, Moon Tasson L, et al. Quantification of von Willebrand factor and ADAMTS-13 after traumatic injury: a pilot study. Trauma Surg Acute Care Open. 2021;6(1):e000703. doi:10.1136/tsaco-2021-000703

8. Edvardsen MS, Hansen ES, Ueland T, et al. Impact of the von Willebrand factor-ADAMTS-13 axis on the risk of future venous thromboembolism. J Thromb Haemost. 2023;21(5):1227-1237. doi:10.1016/j.jtha.2023.01.024

9. Rieger M, Mannucci PM, Kremer Hovinga JA, et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood. 2005;106(4):1262-1267. doi:10.1182/blood-2004-11-4490

Day(s) Performed

Varies

Report Available

7 to 15 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

83520

LOINC Code Information

Test ID Test Order Name Order LOINC Value
ADMAB ADAMTS 13 Antibody, P 40824-5

 

Result ID Test Result Name Result LOINC Value
623136 ADAMTS 13 Antibody 40824-5
623272 Interpretation 69049-5